NASDAQ · CVKDHealthcarePharmaceuticals

Cadrenal Therapeutics news

$1.10−1.87%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About Cadrenal Therapeutics

Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes

GlobeNewswire Inc.Mar 12, 8:00 AM ET▲ Positive

The company announced encouraging preclinical research supporting its lead drug candidate CAD-1005 with demonstrated therapeutic benefits in reducing inflammation and improving metabolic markers in obesity and diabetes models. Additionally, Phase 2 HIT trial results showed greater than 25% reduction in thrombotic events, supporting clinical advancement and potential for multiple indications.

Also mentions CVKD

Articles that tag CVKD but are mainly about other companies.

None recently.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology